NASUS PHARMA LTD (NSRX) Forecast, Price Target & Analyst Ratings
NYSEARCA:NSRX • IL0012181553
4.85 USD
-0.15 (-3%)
Last: Mar 5, 2026, 10:42 AM
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for NASUS PHARMA LTD (NSRX).
Forecast Snapshot
Consensus Price Target
$20.91
+ 331.13% Upside
Next Earnings Forecast
Release DateN/A
PeriodQ1 / 2025
EPS Estimate-$0.04
Revenue Estimate
ChartMill Buy Consensus
82.50%
Weighted Analyst Rating Score
Price Target Details & History
Consensus Price Target and Range
Mean target
$20.91
Upside
+ 331.13%
From current price of $4.85 to mean target of $20.91, Based on 8 analyst forecasts
Low
$19.19
Median
$20.91
High
$23.10
Price Target Revisions
1 Month
0.00%
3 Months
-6.82%
Price Target Summary
8 analysts have analysed NSRX and the average price target is 20.91 USD. This implies a price increase of 331.13% is expected in the next year compared to the current price of 4.85.
The average price target has been revised downward by 6.82% in the past 3 months.
Analyst Ratings & History
Current Analyst Ratings
Analyst Ratings History
Analyst Ratings Consensus
ChartMill Buy Consensus
82.50%
NSRX was analyzed by 8 analysts. The buy percentage consensus is at 83. So analysts seem to be very confident about NSRX.
In the previous month the buy percentage consensus was at a similar level.
NSRX was analyzed by 8 analysts. More opinions would make the average more meaningful.
Recent Upgrades & Downgrades
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2025-12-18 | Citizens | Initiate | Market Outperform |
| 2025-09-29 | Laidlaw & Co. | Initiate | Buy |
Next Earnings Forecast Details
Next Earnings Details
Release DateN/A
PeriodQ1 / 2025
EPS Estimate-$0.04
Revenue Estimate
Revenue Q2QN/A
EPS Q2QN/A
Number of Analysts4
Next Earnings Revisions
Revenue (1 Month)
N/A
Revenue (3 Months)
N/A
EPS (1 Month)
3.49%
EPS (3 Months)
N/A
Next Earnings Summary
Full Analyst Estimates
Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates
| 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | ||
|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | N/A | N/A | N/A | ||||
| EBITDA YoY % growth | N/A | N/A | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | -4.1K | -2.3K 43.90% | -2.2K 4.35% | N/A -248,061.36% | N/A -249.90% | N/A -61.89% | |
| Operating Margin | N/A | N/A | N/A | N/A | N/A | N/A | |
| EPS YoY % growth | N/A | N/A | N/A | N/A | N/A -44.53% | N/A -19.19% |
All data in USD
Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates
| Q1 / 25 | Q2 / 25 | Q3 / 25 | Q4 / 25 | |
|---|---|---|---|---|
| EPS Q2Q % growth | -0.04 | -0.07 | -0.14 | -0.39 |
| Revenue Q2Q % growth | N/A | |||
| EBITDA Q2Q % growth | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | -270.3K | -705.84K -141,068.00% | -1.809M | -4.8M -436,274.55% |
All data in USD
Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data
Long Term Forward Growth Forecast Summary
Long Term EPS Growth (CAGR)
EPS Next 3 Year
-1,488.99%
EPS Next 5 Year
N/A
Long Term Revenue Growth (CAGR)
Revenue Next 3 Year
N/A
Revenue Next 5 Year
N/A
Long Term EBIT Growth (CAGR)
EBIT Next 3 Year
N/A
EBIT Next 5 Year
N/A
NASUS PHARMA LTD / NSRX Forecast FAQ
What is the average price target for NASUS PHARMA LTD (NSRX) stock?
8 analysts have analysed NSRX and the average price target is 20.91 USD. This implies a price increase of 331.13% is expected in the next year compared to the current price of 4.85.
What are the consensus estimates for NSRX stock next earnings?
The consensus EPS estimate for the next earnings of NASUS PHARMA LTD (NSRX) is -0.04 USD and the consensus revenue estimate is 0 USD.
What is the consensus rating for NSRX stock?
The consensus rating for NASUS PHARMA LTD (NSRX) is 82.5 / 100 . This indicates that analysts generally have a positive outlook on the stock.